{rfName}
SE

Indexed in

License and use

Citations

1

Altmetrics

Analysis of institutional authors

Cajal, TeresaAuthor

Share

July 30, 2024
Publications
>
Correction
Hybrid Gold

SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022) (May, 10.1007/s12094-023-03203-8, 2023)

Publicated to:Clinical & Translational Oncology. 25 (9): 2759-2759 - 2023-06-05 25(9), DOI: 10.1007/s12094-023-03229-y

Authors: Garcia-Saenz, Jose Angel; Blancas, Isabel; Echavarria, Isabel; Hinojo, Carmen; Margeli, Mireia; Moreno, Fernando; Pernas, Sonia; Cajal, Teresa; Ribelles, Nuria; Bellet, Meritxell

Affiliations

Granada Univ, Hosp Univ San Cecilio, Inst Invest Biosanit Granada Ibs Granada & Med De, Granada, Spain - Author
Hosp Clin San Carlos, Med Oncol Dept, Inst Invest Sanitaria San Carlos IdISSC, CIBERONC, Madrid, Spain - Author
Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, CIBERONC, Madrid, Spain - Author
Hosp Santa Creu Santa Pau, Barcelona, Spain - Author
Hosp Univ Marques Valdecilla, Santander, Spain - Author
Hosp Univ Reg & Virgen Victoria IBIMA, UGCI Oncol Interctr, Malaga, Spain - Author
Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Barcelona, Spain - Author
ICO Badalona Hosp Germans Trias Pujol, Inst Catala Oncol, Badalona Appl Res Grp Oncol & CARE Translat Progr, B ARGO,HospGermans Trias & Pujol, Badalona, Spain - Author
LHosp Llobregat, Inst Catala Oncol ICO LHosp, Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain - Author
See more

Abstract

Keywords

BiotecnologíaCancer researchCiências biológicas iCiências biológicas iiEngenharias iiFarmaciaMedicina iMedicina iiMedicina veterinariaMedicine (miscellaneous)OdontologíaOncologySaúde coletiva

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Clinical & Translational Oncology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2023, it was in position 157/322, thus managing to position itself as a Q2 (Segundo Cuartil), in the category Oncology. Notably, the journal is positioned en el Cuartil Q2 para la agencia Scopus (SJR) en la categoría Medicine (Miscellaneous).

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-07-20:

  • Open Alex: 1
  • Europe PMC: 1

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-20:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 34 (PlumX).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Granada.